Engineered immune cells take on brain cancer in early trial
NCT ID NCT07555561
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment for patients with relapsed or hard-to-treat lymphoma in the brain or spinal cord. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to check safety and see if the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A patient's own immune cells (T cells) are modified in a lab to recognize and attack lymphoma cells in the brain and spinal cord.
- What this could lead to
- If it works, this could offer a new treatment option for patients with hard-to-treat lymphoma in the central nervous system.
- What could go wrong
- This is a very early (phase 1) and small trial (30 people), so it may not show clear benefit. The therapy also carries risks like severe immune reactions or brain swelling.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Boren Hospital
Beijing, Fengtai District, 100070, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.